Hemp Stocks

502 Kommentare / 0 neu
03.01.2014 11:44
#1
Bild des Benutzers b00n
Offline
Kommentare: 2478
Hemp Stocks

 

 

Uruguay, Colorado Konsum legal

Div. US Bundesstaaten haben Medizinisches Marijane legalisiert...

weitere werden folgen..

nebst uruguay werden wohl noch andere Staaten in America sur folgen.

 

ganzer Sektor hat also enormes Wachstumpotential.

jetzt gilt es mal den spreu vom weizen zu trennen.

 

 

Ich fange mal an..

 


 

Aufklappen

----gesperrt wegen gutmenschentum, wünsche an der stelle allen alles gute, wie immer. http://investorshub.advfn.com/boards/profilea.aspx?user=193864

vor 4 Stunden 21 Minuten
Bild des Benutzers petra129
Offline
Kommentare: 8

Blaues Hufeisen hat am 29.09.2016 - 14:31 folgendes geschrieben:

Schaut euch lieber mal Lifestyle Delivery Systems (LDS in Kanada, LD6 in Frankfurt) an, habe hier im Forum am 11.8. einen Beitrag platziert. Damals stand die Aktie bei rund CAD 0.20. Aktuell bereits bei CAD 0.55, Umsätze täglich mehrere hunderttausend Aktien. Seit August geht die Post ab, weil das Unternehmen die Bewilligung zum Hanfanbau erhalten hat.

....das Problem ist, dass die meisten die ich hatte (APH.V, CGC.TO, EMH.V) und auch Deine LDS sind so steil nach oben gestiegen, dass ich leider alle zu früh verkauft habe, prozentual super Gewinne in reellen Fränkli bescheidener - aber ich bin mehr als zufrieden. Der erneute Einstieg ist dann immer schwierig wenn nicht sogar negativ.....im Moment habe ich noch OGI.V und MT.V etwas konservativer - na ja abwarten. Jedenfalls eine äusserst sympathische Branche!!!

 

vor 7 Stunden 58 Minuten
Bild des Benutzers Blaues Hufeisen
Offline
Kommentare: 601

Schaut euch lieber mal Lifestyle Delivery Systems (LDS in Kanada, LD6 in Frankfurt) an, habe hier im Forum am 11.8. einen Beitrag platziert. Damals stand die Aktie bei rund CAD 0.20. Aktuell bereits bei CAD 0.55, Umsätze täglich mehrere hunderttausend Aktien. Seit August geht die Post ab, weil das Unternehmen die Bewilligung zum Hanfanbau erhalten hat.

28.09.2016 19:29
Bild des Benutzers 2brix
Offline
Kommentare: 1647

petra129 hat am 28.09.2016 - 18:38 folgendes geschrieben:

http://www.stockhouse.com/companies/bullboard/v.aph/aphria-inc-?postid=2...

Schade - schreibt kaum noch jemand?!?!?!

Hoi Petra

Ja ist leider so....

bin mir gerade NSP am anschauen, weiss aber noch nicht viel bzw obs hier reinpasst.

Naturally Splendid Enterprises Ltd(CVE:NSP) Gruss 2b

28.09.2016 18:38
Bild des Benutzers petra129
Offline
Kommentare: 8
Cannabis in Canada
29.08.2016 21:06
Bild des Benutzers Selector
Offline
Kommentare: 286

Ich bin nicht grad begeistert, der Kurs reagiert auch nicht so.

29.08.2016 18:20
Bild des Benutzers 2brix
Offline
Kommentare: 1647

Danke für die Info.

Auf den ersten Blick sehen die Zahlen für mich ugut aus, aber auf den zweiten Blick weiss ich nicht so recht....

29.08.2016 13:28
Bild des Benutzers Selector
Offline
Kommentare: 286
CGC-Q1/2016

Bin grad nicht dabei.-

Zahlen per Ende Juni von CGC (Q1)

http://www.newswire.ca/news-releases/canopy-growth-reports-first-quarter-fiscal-2017-financial-results-591583761.html

 

 

Canopy Growth loses $3.94-million in fiscal Q1 2017

 

2016-08-29 06:50 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH REPORTS FIRST QUARTER FISCAL 2017 FINANCIAL RESULTS

Canopy Growth Corp. has released its financial results for the first quarter of fiscal 2017 ended June 30, 2016.

Consolidated financial results include the accounts of the Company and its wholly owned subsidiaries Tweed Inc. ("Tweed"), Tweed Farms Inc. ("Tweed Farms") and Bedrocan Canada Inc. ("Bedrocan Canada").

First Quarter Fiscal 2017 Highlights

-Revenues of $7.0 million, representing a greater than 300% increase over the three months ended June 30, 2015 and a 39% increase over fourth quarter fiscal year 2016 -Over 16,500 registered patients at June 30, 2016 compared to over 3,600 at June 30, 2015 -Bedrocan began licensed sales of bedro-oils cannabis oil in June 2016 -Announced partnership with AusCann Group Holdings Ltd. of Australia to work together in the Australian and International markets -Announced creation of joint venture, Bedrocan Brazil, with Sao Paulo, Brazil‑based Entourage Phytolab S.A. and local Brazilian partners

Subsequent to First Quarter Fiscal 2017

-Announced business partnership and receipt of necessary regulatory approvals to export medical cannabis to Germany for sale to patients -Listed common shares on the Toronto Stock Exchange -Closed the previously announced bought deal, including the over-allotment option by the underwriters, on August 24, 2016 for gross proceeds of $34.5 million.

"Our business took many important steps forward, in both Canada and abroad, during the first quarter," said Bruce Linton, Chairman & CEO, Canopy Growth. "Continued investment helped our business deliver its eighth consecutive quarter of double digit percentage growth in revenue, product sold and registered patients. During the quarter we brought the full Tweed Farms greenhouse, all 350,000 square feet, into production. With close to 600,000 sq. ft. in production across the corporation, in both low cost greenhouse and indoor growing facilities, the capability and flexibility that we have to produce large quantities of high quality dried cannabis and extracts, to meet potential future market demand, is unmatched in the sector."

Added Linton "Investment in international development drove agreements with partners in Australia, Brazil, and Germany. With other opportunities presenting themselves, the global expansion of our business has just begun."

First Quarter Fiscal 2017 Revenue Review

Revenue for the fourth quarter was $7.0 million compared to revenue of $1.7 million in the three months ended June 30, 2015 and $5.0 million for the fourth quarter of fiscal year 2016.

First Quarter Fiscal 2017 Product Sales Review

In the first quarter of fiscal 2017 ended June 30, 2016, the Company sold approximately 984 kilograms and kilogram equivalents at an average price of $7.09 per gram. In the three-month period ended June 30, 2015, approximately 215 kilograms were sold at an average price of $7.74 per gram. The impact of Bedrocan's True Compassionate Pricing program, introduced in the fourth quarter of fiscal 2016, reduced the average selling price per gram.

First Quarter Fiscal 2017 Gross Margin Review

The gross margin was $3.4 million, or 49% of revenue, for the three month period ended June 30, 2016. In the comparative period last year, the gross margin on the same basis was $4.1 million or 239% of revenue.

First Quarter Fiscal 2017

Adjusted Product Contribution Review

The Company's "Adjusted Product Contribution"1 is a Non-GAAP metric used by management which adjusts the reported gross margin by excluding the fair value measurements as required by IFRS and measures the cost of sales for the grams actually sold in the period. Management believes this measure provides useful information as it reflects the gross margin based on the Company's weighted average cost per gram from seed to sale against the grams sold.

The Adjusted Product Contribution in the first quarter of fiscal 2017 was $4.4 million, or 63% of revenue. In the comparative period last year, the Adjusted Product Contribution was $1.0 million, or 60% of revenue.

First Quarter Fiscal 2017 Operating Expense Review

For the three months ended June 30, 2016, sales and marketing expenses were $2.3 million, or 32% of revenue (three months ended June 30, 2015 - $1.0 million, or 59% of revenue).

The increase in sales and marketing expenses in the three months ended June 30, 2016 over the comparison period was due to expansion of the customer care center, launching Tweed's customer engagement locations, an expanded medical outreach program and continuing to position the Tweed brand in preparation for a non-medical market.

General and Administrative ("G&A") expenses were $2.9 million, or 41% of revenue, in the three-month period ended June 30, 2016 compared to $1.4 million, or 83% of revenue, in the same period last year.

The increase in G&A expenses over the comparison period last year reflects the Company's growth over last year, building commercial capacity and capability as a public company and meeting compliance requirements with Health Canada.

First Quarter Fiscal 2017 Earnings Review

The Company reported a net loss of $3.9 million or $0.04 per basic and diluted share for the first quarter ended June 30, 2016, compared to net income of $1.0 million or $0.02 per basic and diluted share in the comparison period last year. The net loss was inclusive of the non-cash unrealized gain on changes in fair value of biological assets described above. The non-cash gain on biological assets more than offset other cost of sales and operating expenses in the first quarter of last year to produce positive net income.

First Quarter Fiscal 2017 Balance Sheet and Cash Flow Review

At June 30, 2016, the Corporation's cash, comprised of cash and cash equivalents totalled $19.5 million, representing an increase of $4.1 million from March 31, 2016. The increase is attributable to net proceeds from the April 2016 "bought deal" common share offering in the first quarter of the fiscal year 2017 and the exercise of options and warrants together totalling $11.5 million partially offset by cash used to fund operations, investments in facility enhancements and international development together totalling $7.4 million. Investments in facility enhancements were primarily improvements at our Smiths Falls facility including the conversion of growing rooms, in the expansion of cannabis oil extract production capacity and in information technology.

The Audited Consolidated Financial Statements and Management's Discussion and Analysis documents have been filed with SEDAR and are available on www.sedar.com. The basis of financial reporting in the Unaudited Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis documents has been revised to thousands of Canadian dollars, unless otherwise indicated.

Subsequent Events

Tweed Receives Approval to Begin Export of Medical Cannabis to Germany

On July 25, 2016, the Corporation announced that wholly-owned subsidiary Tweed had received the necessary approvals in Canada and Germany to begin exporting medical cannabis for sale to German patients. Working with MedCann GmbH Pharma and Nutraceuticals ("MedCann"), a privately held pharmaceutical importer and manufacturer, the transfer marks an important milestone for the Company and the first known incidence of dried cannabis being exported from a Canadian licensed producer to a major G7 country.

Canopy Growth Corporation Announces Graduation to TSX

On July 25, 2016, the Company announced that is has received final approval for the listing of the Corporation's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX"). The Common Shares commenced trading on the TSX effective as of the open of the market on July 26, 2016 under the symbol "CGC". The Corporations shares were delisted from the TSX Venture Exchange prior to the commencement of trading on July 26, 2016.

Bought Deal Financing

On August 24, 2016, the Company announced that it had closed its previously announced short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 9,453,000 common shares in the capital of the Company were sold at a price of $3.65 per Share, for aggregate gross proceeds of $34,503,450 ("the Offering"). The Offering was underwritten by a syndicate of underwriters co-led by Dundee Securities Ltd. and GMP Securities L.P and including INFOR Financial Inc. and PI Financial Corp.

Regulatory Change

On August 11, 2016, Health Canada announced the new Access to Cannabis for Medical Purposes Regulations (the "ACMPR") which will come into force on August 24, 2016, replacing the MMPR as the regulations governing Canada's medical cannabis program. While the general policy of the ACMPR was disclosed by Health Canada on August 11, 2016, exact regulations will not be available until on or about August 24, 2016. The ACMPR is being implemented as a result of the Federal Court ruling in the case of Allard v. Canada (the "Allard Decision"). In the Allard Decision the Federal Court found the MMPR to be unconstitutional and of no force and effect, but suspended its declaration of invalidity for six months in order to give the government time to respond. As per Health Canada's statement and corresponding fact sheet released on August 11, 2016, the ACMPR will allow Canadians who have been authorized by their health care practitioner, and who are registered with Health Canada, to produce a limited amount of medical marijuana for their own medical purposes, or to designate someone who is registered with Health Canada to produce it for them. Starting materials such as plants or seeds are to be obtained from Licensed Producers only. On August 24, 2016, the government released legislation to enact the policy announcement made on August 11, 2016.

Note 1: The Adjusted Product Contribution is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Adjusted Product Contribution is reconciled and explained in Management's Discussion & Analysis under "Adjusted Product Contribution (Non-GAAP Measure)", a copy of which has been filed today on www.sedar.com .

Webcast and Conference Call Information

Canopy Growth will host a conference call and audio webcast with Bruce Linton, CEO and Tim Saunders, CFO at 8:30 AM Eastern Time today.

Webcast Information

A live audio webcast will be available at:

http://event.on24.com/r.htm?e=1228175&s=1&k=C0DAE17790A73E74952EDF46ABFE...

Calling Information

Toll Free Dial-In Number: 1-888-231-8191

International Dial-In Number (647) 427-7450

Conference ID: 52385525

Replay Information

A replay of the call will be accessible by telephone until 11:59 PM ET on September 19, 2016.

Toll Free Dial-in Number: 1-855-859-2056

Replay Password: 52385525

 

                                                                                                                      
Condensed interim consolidated statements of net (loss) income and comprehensive
(loss) income
(In thousands, except per share)

                                                         Three months ended June 30,
                                                        2016                   2015

Revenue                                           $    6,984             $    1,710

Unrealized gain on changes in fair
value of biological assets                            (6,684)                (5,275)
Inventory expensed to cost of sales                    6,654                  1,492
Production costs                                       3,569                  1,398
Cost of sales (recovery), net of the
unrealized gain on changes in fair
value of biological assets                             3,539                (2,385)
Gross margin                                           3,445                  4,095

Sales and marketing                                    2,260                  1,009
Research and development                                 403                     38
General and administration                             2,850                  1,415
Share of loss in equity investments                      220                      -
Share-based compensation expense                         888                    372
Depreciation and amortization                            911                    268
                                                       7,532                  3,102
(Loss) income from operations                        (4,087)                    993


Interest income (expense), net                          (47)                     19
(Increase) decrease in fair value of
acquisiton consideration related
liabilities                                             (12)                      -
                                                        (59)                     19
Net (loss) income and comprehensive
(loss) income before income taxes                    (4,146)                  1,012

Income tax recovery                                      197                      -
Net (loss) income and comprehensive
(loss) income after income taxes                     (3,949)                  1,012

Net (loss) income per share, basic:                   (0.04)                   0.02
Net (loss) income per share, diluted:                 (0.04)                   0.02

 

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

22.08.2016 16:56
Bild des Benutzers 2brix
Offline
Kommentare: 1647

Selector hat am 15.08.2016 - 15:31 folgendes geschrieben:

Sorry war weg und habe dich nicht gesehen. Ich habe realisiert und beobachte weiter. Falls ich einen guten Wiedereinstieg erwische ok, sonst far well.

kein problem und danke, war auch weg Smile

bin gespannt was kommt. Bin jedenfalls noch drin.

22.08.2016 16:53
Bild des Benutzers Selector
Offline
Kommentare: 286

Würden sie denn ins Thema passen?

 

 

Canopy Growth to release fiscal Q1 2017 results Aug. 29

 

2016-08-22 06:58 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH TO ANNOUNCE FIRST QUARTER FISCAL 2017 FINANCIAL RESULTS

Canopy Growth Corp. will release its financial results for the first quarter of fiscal 2017, the three-month period ended June 30, 2016, on Aug. 29, 2016.

Following the release of its first quarter fiscal 2017 financial results, Canopy Growth will host a conference call and audio webcast with Bruce Linton, chief executive officer, and Tim Saunders, chief financial officer, at 8:30 a.m. ET the same day.

Webcast information

A live audio webcast will be available.

Calling information:

 

Toll-free dial-in number:  1-888-231-8191

International dial-in number:  647-427-7450

Conference ID:  52385525

 

Replay information

A replay of the call will be accessible by telephone until 11:59 p.m. ET on Sept. 23, 2016:

 

Toll-free dial-in number:  1-855-859-2056

Replay password:  52385525

 

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

 

 

18.08.2016 22:11
Bild des Benutzers petra129
Offline
Kommentare: 8
Buy-Buy Or Bye-Bye?
15.08.2016 15:31
Bild des Benutzers Selector
Offline
Kommentare: 286

Sorry war weg und habe dich nicht gesehen. Ich habe realisiert und beobachte weiter. Falls ich einen guten Wiedereinstieg erwische ok, sonst far well.

News

  

Canopy Growth appoints Zekulin as president

 

2016-08-15 08:04 ET - News Release

 

Mr. Bruce Linton reports

MEDICAL CANNABIS INDUSTRY PIONEER ADAM GREENBLATT JOINS TWEED AND MARK ZEKULIN APPOINTED PRESIDENT OF CANOPY GROWTH CORPORATION

Canopy Growth Corp. is welcoming Adam Greenblatt as the head of Quebec engagement at its wholly owned subsidiary Tweed Inc. Mark Zekulin, President of Tweed, has also taken on the additional role of President of Canopy Growth Corporation.

"Mark has demonstrated outstanding vision and organizational execution from the founding of Tweed to the achievement of our 20,000th patient," said Bruce Linton, CEO and Chairman of Canopy. "The Company is now engaged in the pursuit of medical, recreational and international opportunities and Mark fits naturally in this new role."

At the same time, Adam Greenblatt has stepped down from his role at Quebec's leading medical cannabis clinic, Sante Cannabis, in order to further expand access for patients in Canada's second most populous province on behalf of Tweed.

"Adam's appointment is an important step in our commitment to fair and equal access to medical cannabis patients across the country," said Mark Zekulin. "In addition to his unparalleled wit on social media, Adam Greenblatt is a pioneer in the cannabis community and we are excited to have him join us here at Tweed."

Mr. Greenblatt has stepped down from his role at Quebec's leading medical cannabis clinic, Sante Cannabis, in order to further expand access for patients in Canada's second most populous province on behalf of Tweed.

Mr. Greenblatt's time as Executive Director of Sante Cannabis was marked by an ability to positively influence provincial cannabis policies, obtaining intervenor status at the Supreme Court of Canada in R v. Smith, and collaborating in the Quebec Cannabis Registry -- all while helping patients obtain safe and legal access to medical cannabis under the Marihuana for Medical Purposes Regulations (MMPR).

Quebec is underrepresented in the MMPR, with less than 5% of authorized patients residing in the province, despite representing almost 25% of Canada's population. More than half of patients in Quebec that have gained access to medical marijuana under the MMPR have accessed the system with support from Sante Cannabis.

"There are more barriers to safe and legal access to medical cannabis in Quebec than elsewhere in Canada," said Adam Greenblatt. "Joining the Tweed team will empower me to engage patients and healthcare professionals, and to further establish a vibrant and professional marijuana industry in the province of Quebec."

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

12.08.2016 12:48
Bild des Benutzers 2brix
Offline
Kommentare: 1647

nimmst du gewinn mit oder machst zu einen Zock, also aussteigen und dann später wieder einsteigen?

12.08.2016 12:38
Bild des Benutzers Selector
Offline
Kommentare: 286

Hier auch noch wieder interessante News, zwischendurch mal Realisieren habe ich mir gestern auch gegönnt.

 

Canopy says new cannabis rules a setback to good policy

 

2016-08-11 15:16 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION RESPONDS TO PROPOSED NEW CANNABIS REGULATIONS

Canopy Growth Corp., parent company of licensed producers Tweed Inc., Bedrocan Canada Inc. and Tweed Farms Inc. is providing the following response to today's announcement. Today, the government of Canada announced that regulations governing medical marijuana would be amended, as expected, by Aug. 24, 2016, and that the majority of the previously repealed marijuana medical access regulations (MMAR) would form a part of an interim system, introduced to satisfy the requirements set out by the courts in the truncated timeline the government was given to respond.

For the company's patients and the 95 per cent of people who do not abuse the privilege of growing at home, this is positive news. The company has openly supported the right of patients to grow at home, and it welcomes this new option for patients. Choice is a good thing, and those who wish to grow moderate amounts of cannabis at home for personal consumption should be allowed to do so.

For Tweed and Bedrocan Canada, it truly is business as usual. The reality in Canada today is that patients already have significant choice. Legal or not, many people already choose to grow at home or to access cannabis through an illegal dispensary. In addition, they can choose from over 30 licensed producers of cannabis.

Since the company began three years ago as a start-up business in Smiths Falls, it has been the company's mission to offer products and services that stand out among these options. Patients have always had choice, and the company has never taken that for granted.

Today, Canopy Growth is proud to welcome its 20,000th customer to join the Canopy family. As of today, the company has garnered the trust and support of over 20,000 Canadians, representing more than half of all those who ever joined the MMAR system in its 13 years of existence. The company offers its customers a convenient way to access a wide variety of cannabis products produced to the highest-quality standards in the world.

The company has taken great strides to normalize medical cannabis use through political advocacy, physician education and stakeholder outreach. The company is confident that through its work, it has improved access to medical cannabis for tens of thousands of Canadians. The company will continue this important work until medical cannabis is fully incorporated into the Canadian health care system.

Adhering to the strict quality-assurance regulations developed by Health Canada, Tweed, Tweed Farms and Bedrocan Canada have proven their ability to produce products that provide physicians and patients with peace of mind. The company is confident that, given the option, its ability to produce world-class products in a cost-effective manner will be the preferred method for the vast majority of Canadians.

So where to now?

While the company supports a patient's right to grow at home, the MMAR and the grow-at-home system it represents is not good policy. All of the flaws that existed in 2013 when the government concluded after extensive consultation that the MMAR presented elevated diversion risks, abuse of plant limits and an inability for law enforcement to know legal from illegal cannabis -- still exist today.

While the company believes this is a short-term initiative, with a broader overhaul of cannabis policy expected in the coming months, it is still a setback for the advancement of sound cannabis policy and Canada's global leadership in cannabis regulation.

Though the company cannot control government policy, it can control what it does with it. To the extent this short-term opportunity allows the company, it wants to help customers explore grow at home outside their home. The company will rent you the space, genetics and supplies, and it will help you to grow your own plants at its (non-MMPR) facilities. Home grow without your home, only from Tweed.

Make no mistake: In the company's view, there is no substitute for clean, convenient, quality-assured cannabis at competitive prices. But if you want to grow your own cannabis, Tweed would be proud to assist you in that journey, insofar as the rules allow. Maybe yet another option from your friends at Tweed.

11.08.2016 12:56
Bild des Benutzers Blaues Hufeisen
Offline
Kommentare: 601

Lifestyle Delivery Systems (Symbol LD6 in Frankfurt) erhält Genehmigung zum Anbau und Produktion von Marijuana-Produkten!

http://www.finanzen.net/nachricht/aktien/DGAP-News-Lifestyle-Delivery-Sy...

08.08.2016 17:14
Bild des Benutzers Emil
Offline
Kommentare: 604

Danke noch für die Info. Ich habe am letzten Freitagabend noch Kasse gemacht. War hier eine ganz gute Zeit. Vielleicht mal wieder? Inzwischen

Feriengrüsse

Emil

05.08.2016 18:48
Bild des Benutzers Selector
Offline
Kommentare: 286

 

Ja und heute nochmals sehr interessante, gute News:

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2395414

Man beachte Abs. 5

Canopy Growth closes $5.5-million in loan facilities

 

2016-08-05 10:18 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH SECURES $5.5 MILLION IN LOAN FACILITIES

Canopy Growth Corp. has closed a $5.5-million financing with a commercial lending institution. The two facilities, which will be used to refinance building construction and for expenditures related to the purchase of capital equipment, is the second financing agreement that the institution has entered into with Canopy Growth. The three facilities total approximately $7-million.

"These new facilities strengthen our financial position and enable Canopy Growth to continue driving forward an aggressive expansion of our operations that we believe is necessary to help meet future cannabis market demand," said Bruce Linton, and chief executive officer of Canopy Growth. "We are very pleased with this second round of financing seeing as it is the first time that the commercial lender has entered into multiple credit agreements with a licensed producer. We believe it signals a strong belief in the strength of Canopy Growth's current and future potential business."

The new financing comprises two separate loan facilities: a term loan and a revolving line of credit. The five-year term loan is for approximately $3.5-million and is provided on commercial terms. The revolving loan, in the amount of $2-million, bears a variable interest rate based on the Canadian Imperial Bank of Commerce prime rate with a five-year term and interest-only payments.

The financing is secured by a first-charge mortgage on the Tweed Farms property, a first position on a Tweed Farms general security agreement and a specific security interest, backed by a corporate guaranty from Canopy Growth.

Mr. Linton commented, "Management believes it is appropriate and necessary to fund continued investment in our business in order to capitalize on Canadian and international opportunities in a timely fashion, all the while considering the potential impact of key future developments in our sector, including pending changes to the marijuana for medical purposes regulations (MMPR) in response to the Allard decision, which are expected to be introduced by Aug. 24, 2016; the tabling of recommendations by the federal government's marijuana legalization task force, which is expected in November, 2016; and the introduction of marijuana legalization legislation, which is expected to happen by the spring of 2017."

The first regulatory change on the horizon is expected this month when the Canadian government is likely to announce changes to the MMPR in response to the decision rendered on Feb. 24, 2016, by the federal court in the case of Allard et al. versus Canada. The company believes that the legislative changes are likely to result in the government permitting patients to grow medical marijuana for their own use. While such changes may result in a material adverse change to the company and sector, Canopy remains committed to an expansion of capacity that appropriately invests in the future of the cannabis sector.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

04.08.2016 17:50
Bild des Benutzers 2brix
Offline
Kommentare: 1647

jetzt nimmt der Kurs von CGC aber recht Fahrt auf. Die upgrade auf TSX wird sich auszahlen.

3.82 +0.23 (6.41%)

 

25.07.2016 17:44
Bild des Benutzers Selector
Offline
Kommentare: 286

Was den Anleger freut, wer noch dabei ist:

SmileDirol

 

Canopy Growth receives OK to export pot to Germany

 

2016-07-25 08:16 ET - News Release

 

Mr. Bruce Linton reports

TWEED: COMING TO A GERMAN PHARMACY NEAR YOU - CANADIAN MARKET LEADER ANNOUNCES APPROVALS TO HAVE TWEED PRODUCTS AVAILABLE FOR SALE TO GERMAN PATIENTS THIS SUMMER

Canopy Growth Corp.'s wholly owned subsidiary, Tweed Inc., has received necessary approvals in Canada and Germany to begin export of medical cannabis for sale to German patients.

Working with MedCann GmbH Pharma and Nutraceuticals ("MedCann"), a privately held pharmaceutical importer and manufacturer, the transfer marks an important milestone for the Company and the first known incidence of dried cannabis being exported from a Canadian licensed producer to a major G7 country.

"Introducing Tweed product to German medical cannabis patients is an exciting and groundbreaking event," said Bruce Linton, Chairman and CEO of Canopy Growth. "Patients will soon have a new choice in variety for their medical cannabis, and we are honoured to be involved in the changing landscape for German access and choice."

Germans can presently access legal medical cannabis through pharmacies for a variety of medical conditions, though adequate domestic production has not yet been established. Tweed will launch an initial two strains in Germany, and hopes to bring further variety to market as soon as possible.

"As the German population now knows, the regulatory aspects and laws concerning medical cannabis have evolved to address the growing needs of medical cannabis patients in Germany," said Dr. Pierre Debs, co-founder of MedCann. "Now, in the summer of 2016, through the concerted efforts of MedCann and Tweed, patients across Germany can be assured of a new supply and variety of the highest quality medical cannabis."

Building on recent announcements in Australia and Brazil, Canopy has now partnered to bring its products, expertise and brands to four continents. In addition to providing products for sale to the German market, Canopy through its subsidiaries Bedrocan Canada and Tweed, is increasingly focused on the provision of dried cannabis and cannabis oils for the purpose of clinical trials and research to ensure healthcare practitioners, government policy leaders and patients have the best available evidence to make informed decisions on medical cannabis within their regulatory frameworks and practices.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

und 

   

Canopy Growth to graduate to TSX July 26 2016-07-25 09:01 ET - News Release Mr. Tyler Burns reports

  

CANOPY GROWTH CORPORATION ANNOUNCES GRADUATION TO TSX Canopy Growth Corp. has received final approval for the listing of the corporation's common shares on the Toronto Stock Exchange. The common shares will commence trading on the TSX effective as of the open of the market on July 26, 2016. Upon listing on the TSX, the common shares will continue to trade under the symbol CGC. In conjunction with listing on the TSX, the common shares will be delisted from the TSX Venture Exchange prior to the commencement of trading on July 26, 2016. "Being the first cannabis-producing company in North America listed on a major exchange such as the TSX strengthens the sector and is expected to bring Canopy Growth to international institutional investors," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "The TSX is the stock exchange for Canada's banks and elite publicly traded companies, and we hope that the addition of Canopy Growth helps signal that the world's view of cannabis has finally shifted, starting right here in Canada." Added Mr. Linton, "This is a historic day for our company, our sector, our patients and investors." To celebrate this latest milestone, Canopy Growth's founding team and guests will open trading on the TSX on July 26, 2016. The market open ceremony can be watched in real time on YouTube and on BNN television. An archive of the ceremony will also be made available at the TSX's website. We seek Safe Harbor. © 2016 Canjex Publishing Ltd. All rights reserved.

28.06.2016 19:41
Bild des Benutzers Emil
Offline
Kommentare: 604

Ja, denke, kommt insgesamt gut. Die bleiben am Ball und sind mega aktiv. Die Investitionen muss man schon auch beachten und hier ist noch was, das interessant werden dürfte, Joint Venture in Brazil:

http://www.stockwatch.com/News/Itemaspx?bid=Z-C:CGC-2385742

Emil

27.06.2016 19:57
Bild des Benutzers Selector
Offline
Kommentare: 286
CGC Ergebnis 2016

Anbei das Jahresergebnis CGC 2016 und Q4/2016 SmileDirol

Möglich, dass sich noch einige drüber freuen.-

 

Details der Zahlen s. Link

http://www.newswire.ca/news-releases/canopy-growth-corporation-reports-fourth-quarter-and-fiscal-year-2016-financial-results-584500071.html

 

Canopy Growth Corporation Reports Fourth Quarter and Fiscal Year 2016 Financial Results

 

Fiscal year revenues increased 4-fold and licensed production space doubled year over year

SMITHS FALLS, ON, June 27, 2016 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or "the Company") (TSX.V: CGC) today released its financial results for the fourth quarter and fiscal year 2016 ended March 31, 2016.  All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Consolidated financial results include the accounts of the Company and its wholly-owned subsidiaries Tweed Inc. ("Tweed"), Tweed Farms Inc. ("Tweed Farms") and Bedrocan Canada Inc. ("Bedrocan Canada").

Fourth Quarter Fiscal 2016 Highlights

  • Revenues of $5.0 million, representing a greater than 300% increase over the three month period ended March 31, 2015 and a 45% increase over Q3, fiscal year 2016
  • Sale of Tweed 10:1 Cannabis Oil began on February 25, 2016
  • Supported two Canadian licensed producers through the sale of wholesale product during the fourth quarter
  • Over 11,000 registered patients at March 31, 2016 compared to 2,800 at March 31, 2015, and compared to over 8,200 at December 31, 2015, and greater than 16,000 as of today's date
  • Tweed entered into a business partnership with entertainment and cannabis icon, Snoop Dogg
  • Tweed Farms' full 375,000 ft.2 facility licensed to produce, possess and ship dried marijuana
  • Bedrocan launches True Compassionate Pricing program, all six standardized Bedrocan varieties priced at $5.00 per gram for all clients

Fiscal Year 2016 Highlights

  • Revenues of $12.7 million, representing a greater than 430% increase over the fiscal year ended March 31, 2015
  • Acquired Licensed Producer Bedrocan Canada
  • Total licensed production space more than doubled to greater than 550,000 sq. ft.
  • Acquired Licensed Producer applicant MedCannAccess and introduced industry first in-person service through Tweed Main Street locations
  • Cash position of $15.4 million at March 31, 2016

Subsequent to Fourth Quarter and Fiscal Year 2016

  • Completed $11.5 million bought deal
  • Announced partnership with AusCann Group Holdings Ltd. of Australia to work together in the Australian and International markets
  • Received conditional approval to list common shares on the Toronto Stock Exchange. Listing anticipated Q2 2017

"Fiscal 2016 was another year of dramatic change and growth in our business," said Bruce Linton, Chairman & CEO, Canopy Growth. "Investments made across our business, including in our production capacity, in the diversification of our product offering and in our award winning customer service, helped deliver a four-fold increase in revenue, a three-fold increase in registered patients and doubled our licensed production space."

Added Linton "With the prospect of a legal recreational marijuana market in Canada on the horizon and many exciting international business opportunities, we are committed to building on our strong start.  We will continue to make prudent investments in our business to increase our market share, diversify our product offering, grow our production capacity in Canada, vertically integrate up the value chain of permissible products and drive international growth."   

Fourth Quarter and Fiscal Year 2016 Revenue Review

Revenue for the fourth quarter was $5.0 million compared to revenue of $1.2 million in the three months ended March 31, 2015 and $3.5 million for the third quarter of fiscal year 2016.

Revenues for the twelve month fiscal year ended March 31, 2016 were $12.7 million.  In comparison, revenues in the fifteen month period ended March 31, 2015 were $2.4 million.   

Fourth Quarter and Fiscal Year 2016 Product Sales Review

In the fourth quarter of fiscal year 2016, the Company sold approximately 700 kilograms and kilogram equivalents at an average price of $7.16 per gram.  In the three month period ended March 31, 2015, last year, approximately 167 kilograms were sold at an average price of $7.24 per gram. 

Approximately 1,700 kilograms and kilogram equivalents were sold in the fiscal year ended March 31, 2016, representing a greater than 400% increase over the prior fiscal year.

Fourth Quarter and Fiscal Year 2016 Gross Margin Review

The gross margin, including the unrealized gain on changes in fair value of biological assets, in accordance with IFRS, was $2.7 million, or 53% of sales, for the three-month period ended March 31, 2016.  In the comparison period last year, the gross margin on the same basis was $2.4 million or 197% of sales.

In the twelve month period ended March 31, 2016, the gross margin, inclusive of the unrealized gain on changes in fair value of biological assets was $19.0 million or 150% of sales, as compared to $2.8 million, or 119% of sales during the fifteen month period ended March 31, 2015. 

Fourth Quarter and Fiscal Year 2016 Adjusted Product Contribution Review

The Company's "Adjusted Product Contribution"1 is a Non-GAAP metric used by management which adjusts the reported gross margin by excluding the fair value measurements as required by IFRS and measures the cost of sales for the grams actually sold in the period. Management believes this measure provides useful information as it reflects the gross margin based on the Company's weighted average cost per gram from seed to sale against the grams sold. 

The Adjusted Product Contribution in the fourth quarter of fiscal 2016 was $3.2 million, or 63% of sales.  The Adjusted Product Contribution in the twelve month period ended March 31, 2016 was $8.1 million, or 64% of sales.   

Fourth Quarter and Fiscal Year 2016 Operating Expense Review

For the three-month period ended March 31, 2016, sales and marketing expenses were $2.4 million (three months ended March 31, 2015 - $0.7 million).   

In the twelve month fiscal year ended March 31, 2016, sales and marketing expenses were $5.7 million. In comparison, in the fifteen month period ended March 31, 2015, these expenses were $2.7 million.  

The increase in sales and marketing expenses in the three and twelve month periods ending March 31, 2016 over the comparison periods was invested in refreshing Bedrocan Canada post-acquisition, launching Tweed's customer engagement locations and continuing to position the Tweed brand in preparation for a non-medical market.

General and Administrative ("G&A") expenses were $2.6 million in the three-month period ended March 31, 2016 compared to $1.5 million in the same period last year.

In the twelve month period ended March 31, 2016, G&A expenses were $8.2 million. In comparison, in the fifteen month period ended March 31, 2015, G&A expenses were $4.9 million.

The increase in G&A expenses over the comparison periods last year reflects the Company's growth from the early start-up of last year, building commercial capacity and capability as a public company and meeting compliance requirements with Health Canada. 

Fourth Quarter and Fiscal Year 2016 Earnings Review

The Company reported a net loss of $5.1 million or $0.05 per basic and diluted share for the fourth quarter ended March 31, 2016, compared to a net loss of $0.4 million or $0.01 per basic and diluted share in the comparison period last year.

For the twelve months ended March 31, 2016, the net loss amounted to $3.5 million or $0.05 per basic and diluted share, compared to a net loss of $9.3 million or $0.29 per basic and diluted share in the fifteen months ended March 31, 2015.  The net loss was inclusive of the non-cash unrealized gain on changes in fair value of biological assets described above.

Fourth Quarter and Fiscal Year 2016 Balance Sheet and Cash Flow Review

At March 31, 2016, the Company's cash, comprised of cash and cash equivalents totalled $15.4 million, representing a decrease of $9.0 million from March 31, 2015. The decrease is attributable to $12.4 million used to fund operations, investments in facility enhancements totalling $13.1 million, and $2.1 million used to repay a loan, partially offset by net proceeds from financings, including the "bought deal" common share offering in the third quarter of fiscal year 2016 and the exercise of warrants and options, together totalling $20.6 million.  Investments in facility enhancements include the build out of our Tweed Farms facility and improvements at our Tweed facility, in part required for the production of cannabis oil extracts and refinements to production processes.

The Audited Consolidated Financial Statements and Management's Discussion and Analysis documents have been filed with SEDAR and are available on www.sedar.com.  The basis of financial reporting in the Unaudited Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis documents has been revised to thousands of Canadian dollars, unless otherwise indicated.

Subsequent Events

Bought Deal Financing

On April 15, 2016, the Company announced that it had closed its previously announced short-form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 5,002,500 common shares in the capital of the Company were sold at a price of $2.30 per share, for aggregate gross proceeds of $11,505,750 (the "Offering").  The Offering was underwritten by a syndicate of underwriters led by Dundee Securities Ltd and including GMP Securities L.P.

Canopy Growth and AusCann Group Holdings Ltd. Partnership

Canopy Growth announced a partnership with AusCann Group Holdings Ltd. ("AusCann"), an early leader in the nascent Australian medical cannabis industry, in which Canopy Growth will offer the expertise of Tweed and Tweed Farms in a number of areas including production, quality assurance and operations, and provide strategic advisory services to AusCann in exchange for an initial 15% ownership stake in AusCann, as well as future options.  AusCann and Canopy Growth will also aim to work together in Australian and international markets in a preferential but non-exclusive arrangement.

Canopy Growth Corporation Received Conditional Approval from the TSX

On June 8, 2016, the Company announced it had received conditional approval from the Toronto Stock Exchange (TSX) to list its common shares once it had satisfied certain conditions. Canopy Growth will be the first cannabis producer to list on Canada's most prestigious securities exchange. CGC expects to meet all conditions of approval and commence trading on the TSX in the second quarter of fiscal year 2017, the three-month period ending September 30, 2016.

Note 1:  The Adjusted Product Contribution is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.  The Adjusted Product Contribution is reconciled and explained in Management's Discussion & Analysis under "Adjusted Product Contribution (Non-GAAP Measure)", a copy of which has been filed today on www.sedar.com.

Conference Call Details

Canopy Growth will host a conference call and audio webcast with Bruce Linton, CEO and Tim Saunders, CFO at 8:30 AM Eastern Time, June 27, 2016.  

Webcast Information
A live audio webcast will be available at:
http://event.on24.com/r.htm?e=1169137&s=1&k=9465B1E57BBFDE8C19CCC91D5134D10D

Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 86544060

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on July 18, 2016.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 86544060

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms.  Through its wholly‑owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, Canopy Growth operates three state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity.  Canopy Growth has established partnerships with leading sector names in Canada and abroad.  For more information, www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

 

21.06.2016 19:07
Bild des Benutzers logn
Offline
Kommentare: 292

2brix hat am 21.06.2016 - 17:56 folgendes geschrieben:

immer schön von dir zu lesen Selector

Ein herzliches Dankeschön - bin auch noch hier Wink

21.06.2016 17:56
Bild des Benutzers 2brix
Offline
Kommentare: 1647

immer schön von dir zu lesen Selector

21.06.2016 10:14
Bild des Benutzers Selector
Offline
Kommentare: 286

Zur Info, wer hier nochdabei ist:

 

Canopy Growth to release fiscal 2016 financials June 27

 

2016-06-20 11:42 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH TO ANNOUNCE FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL RESULTS

Canopy Growth Corp. will release its financial results for the fourth quarter and fiscal year 2016 ended March 31, 2016, on June 27, 2016.

Following the release of its fourth quarter and fiscal year 2016 financial results, Canopy Growth will host a conference call and audio webcast with Bruce Linton, chief executive officer, and Tim Saunders, chief financial officer, at 8:30 a.m. Eastern Time the same day.

Webcast information

A live audio webcast will be available on-line.

Calling information

 

Toll-free dial-in number:  1-888-231-8191

International dial-in number:  647-427-7450

Conference ID:  86544060

 

Replay information

A replay of the call will be accessible by telephone until 11:59 p.m. ET on July 18, 2016.

 

Toll-free dial-in number:  1-855-859-2056

Replay password:  86544060

 

© 2016 Canjex Publishing Ltd. All rights reserved.

20.06.2016 17:12
Bild des Benutzers Selector
Offline
Kommentare: 286

Nun machen wir auch was in Oel  GoodWink

 

 

Canopy's Bedrocan receives licence to sell cannabis oil

 

2016-06-20 07:45 ET - News Release

 

Mr. Marc Wayne reports

BEDROCAN CANADA LAUNCHES BEDRO-OILS, STANDARDIZED CANNABIS OIL PRODUCTS

Bedrocan Canada Inc., a wholly owned subsidiary of Canopy Growth Corp., has received its Health Canada licence to sell cannabis oils in addition to dried cannabis products. Three varieties are available for sale today with the remaining three standardized Bedrocan varieties following shortly.

New bedro-oils are made by extracting oils from Bedrocan Canada's line of standardized whole-flower cannabis varieties using carbon dioxide supercritical extraction equipment. Once the crude extraction is purified, it is balanced with organic sunflower oil to create a versatile product that can be consumed on its own or used for baking or cooking.

"Many of our clients have expressed a desire to ingest cannabis oils to either complement or substitute the inhaled route," said Marc Wayne, president, Bedrocan Canada. "We're proud to offer this new option for patients who, whether for convenience or for health reasons, prefer to ingest their medical cannabis."

Along with Bedrocan Canada's sister company, Tweed Inc., the company has committed $50,000 toward partnerships with leading organizations committed to responsible use education. One dollar from every bottle of 10-to-1 bedro-oils sold will also go toward important initiatives such as a recently announced partnership with MADD Canada and the Canadian Drug Policy Coalition.

Keeping with Bedrocan Canada's commitment to true compassionate pricing, bedro-oils will be sold for $110 per 100-millilitre bottle.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

08.06.2016 17:50
Bild des Benutzers Selector
Offline
Kommentare: 286

Anbei noch etwas frohe News, die ich euch nicht vorenthalten will:

 Good   Smile  Dirol

 

Canopy Growth receives conditional OK to list on TSX

 

2016-06-08 07:46 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION RECEIVES CONDITIONAL APPROVAL TO LIST SHARES ON TSX

Canopy Growth Corp. has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its common shares on the TSX, representing another major industry first for the company.

Canopy Growth was the first federally approved, publicly traded cannabis producer in North America when it listed on the TSX Venture Exchange in April 2014. It was also the first geographically diversified producer with multiple production licenses and the first in the sector to surpass $100M market capitalization.

"Graduating to the TSX, and to be the first in the sector to achieve it, is a major accomplishment for our team," said Bruce Linton, Chairman and CEO, Canopy Growth. "The sector is growing rapidly and we have focused on maintaining our leadership position as it grows. Listing on the TSX will bring even more visibility and credibility as we pursue domestic and international business."

The Company wishes to thank the TSX Venture Exchange for facilitating its listing since 2014. Public trading has allowed Canopy Growth to operate transparently in an emerging sector that required an unprecedented level of openness in order to be understood. Management welcomes the exposure the new listing will bring from retail investors and institutional managers.

Final approval of the listing is subject to Canopy meeting certain standard requirements of the TSX on or before September 1 st, 2016. The Company expects to satisfy all of the requirements and will make a further announcement once the TSX has issued a bulletin confirming the date on which trading on the TSX will commence. Upon completion of the final listing requirements, Canopy Growth's common shares will be delisted from the TSX Venture Exchange.

Fourth Quarter Financial Results

Financial results for Q4 2016 and FY 2016, the three and 12-month periods ended March 31 st, 2016 will be released prior to the end of June 2016. Additional details, including dial-in information for the quarterly conference call will be released one week prior.

Here's to Future Growth.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

Und wer informiert bleiben will:

https://www.tweed.com/blogs/blog.

 

16.05.2016 18:58
Bild des Benutzers Emil
Offline
Kommentare: 604

Die überschlgen sich ja hier vor lauter neuen Partnerschaften. Seit ich dabei bin ist der Kurs sogar gestiegen. Blum 3

 

Canopy to act as adviser to Australian pot company

 

2016-05-09 07:31 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION HEADS DOWN UNDER

Canopy Growth Corp. has entered a partnership with AusCann Group Holdings Ltd., an early leader in the nascent Australian medical cannabis industry.

Through this partnership, Canopy Growth will offer its expertise in a number of areas, including production, quality assurance and operations, and provide strategic advisory services to AusCann in exchange for an initial 15-per-cent ownership stake in the company as well as further options. AusCann and Canopy Growth will also aim to work together in Australian and international markets in a preferential but non-exclusive arrangement.

"I'm very pleased to enter into this new international relationship, the first of its kind for a Canadian cannabis company," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "As the Australian government begins to lay out a framework for legal medical cannabis, AusCann has the same opportunities and challenges that Tweed and its sister companies faced several years ago. We have confidence that the Australian medical cannabis market will grow similarly to Canada and we think the lessons we learned in our early days will prove invaluable to the team at AusCann."

Mr. Linton will join the AusCann board of directors alongside a world-class leadership team that combines experts from public health, policy-makers and medically focused entrepreneurs. Best practices established at Tweed and Tweed Farms will be shared with AusCann to produce clean, consistent products that Australians can trust.

"We chose to work with Canopy Growth because they've established themselves as leaders in the Canadian and global industry. We are excited to establish the same success here in Australia," said Elaine Darby, managing director, AusCann.

Medical cannabis laws are still being finalized in Australian Parliament, with final implementation expected late 2016 and product expected to go to market in 2017.

The agreement with AusCann remains subject to approval by the TSX Venture Exchange.

Here's to future (Australian) growth.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

Emil

09.05.2016 22:19
Bild des Benutzers Selector
Offline
Kommentare: 286

 

Erneut Erfreuliches zur Info für alle die hier dabei sind, heute gesehen:

 Yes 3

 

Canopy to act as adviser to Australian pot company

 

2016-05-09 07:31 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION HEADS DOWN UNDER

Canopy Growth Corp. has entered a partnership with AusCann Group Holdings Ltd., an early leader in the nascent Australian medical cannabis industry.

Through this partnership, Canopy Growth will offer its expertise in a number of areas, including production, quality assurance and operations, and provide strategic advisory services to AusCann in exchange for an initial 15-per-cent ownership stake in the company as well as further options. AusCann and Canopy Growth will also aim to work together in Australian and international markets in a preferential but non-exclusive arrangement.

"I'm very pleased to enter into this new international relationship, the first of its kind for a Canadian cannabis company," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "As the Australian government begins to lay out a framework for legal medical cannabis, AusCann has the same opportunities and challenges that Tweed and its sister companies faced several years ago. We have confidence that the Australian medical cannabis market will grow similarly to Canada and we think the lessons we learned in our early days will prove invaluable to the team at AusCann."

Mr. Linton will join the AusCann board of directors alongside a world-class leadership team that combines experts from public health, policy-makers and medically focused entrepreneurs. Best practices established at Tweed and Tweed Farms will be shared with AusCann to produce clean, consistent products that Australians can trust.

"We chose to work with Canopy Growth because they've established themselves as leaders in the Canadian and global industry. We are excited to establish the same success here in Australia," said Elaine Darby, managing director, AusCann.

Medical cannabis laws are still being finalized in Australian Parliament, with final implementation expected late 2016 and product expected to go to market in 2017.

The agreement with AusCann remains subject to approval by the TSX Venture Exchange.

Here's to future (Australian) growth.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

27.04.2016 16:49
Bild des Benutzers Selector
Offline
Kommentare: 286

 

Tatsächlich, es geht voran. Sehe heute Erfreuliches:

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2365888

Canopy enrolling medical pot patients with Sask. clinic

 

2016-04-27 06:58 ET - News Release

 

Mr. Mark Zekulin reports

TWEED AND BEDROCAN CANADA COLLABORATE WITH CANNABIS HEALTH CLINIC TO ENROLL CANNABIS DISPENSARY PATIENTS

Tweed Inc. and Bedrocan Canada Inc., with the help of the Cannabis Health Clinic (CHC) in Regina, Sask., have welcomed hundreds of new patients to the marijuana for medical purposes regulations (MMPR) system that were previously accessing medical cannabis through a dispensary. Tweed and Bedrocan Canada are proud to offer high-quality medical cannabis to Canadians who have for years been accessing marijuana from sources outside the MMPR.

This conversion is the result of CHC's decision to shift its business model to a health clinic that will help people access products from companies like Tweed and Bedrocan.

"I started out as a patient and found cannabis to be an effective treatment and then it evolved to a point where I was filling a larger need in the community," said Sean Murray, president of CHC. "Now with Tweed and Bedrocan I can help bridge the gap that exists between patients and producers. The general public needs educational resources and we want to steer people towards the system that's set up to serve them."

CHC patients and customers will now have the peace of mind that comes with being able to lawfully carry, consume and travel within Canada with their much-needed medication.

"We work with partners all across the country who help people access our products," said Mark Zekulin, Tweed's president. "The Cannabis Health Clinic expressed a desire to transition their business and their clientele to the mainstream, regulated system and we're proud to work with them to achieve that goal."

Tweed and Bedrocan started registering CHC customers in February and will continue to on board additional clients moving forward.

Many Canadians have questions about medical cannabis and turn to resources in the community to find information. Tweed operates Main Street community engagement centres in Ontario and also has dozens of certified partner organizations that provide education on legal access points for medical cannabis. These strategies complement each other to create an environment that fosters a broader dialogue and understanding of medical cannabis and improved access where appropriate.

"We're encouraged by the fact that as access and product diversity improves, interest in Tweed is coming from all corners of the industry," said Mr. Zekulin.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

20.04.2016 21:16
Bild des Benutzers Selector
Offline
Kommentare: 286

SmileDirol Das ist ein guter Tag heute, so konnte man mit einem unteren Teil auch mal realisieren.

Allerdings, ich denke, nun geht es voran.

20.04.2016 19:39
Bild des Benutzers Emil
Offline
Kommentare: 604

Danke für die Info, mega super!

Biggrin

Jah, das bringt den Kurs zum Laufen, sehe gerade + 13.33%.

Hier auch noch:

 

Canopy's Tweed completes Smiths Falls expansion

 

2016-04-20 12:37 ET - News Release

 

Mr. Mark Zekulin reports

TWEED INC. SUPPORTS PATIENTS' RIGHTS TO GROW MEDICAL CANNABIS AT HOME

In the spirit of 4/20, Canopy Growth Corp.'s Tweed Inc. has confirmed its support for patients' rights to grow their own medical cannabis supply in their residences. Many Canadians have been legally growing medical cannabis in their homes for over a decade.

Tweed has been shipping cannabis to Canadians for almost two years under the marijuana for medical purposes regulations (MMPR). In that time, the company has provided a consistent, clean supply of cannabis that patients can order on-line and have shipped right to their doors. The MMPR mail-delivery system has proven very popular with more Canadians accessing cannabis through the current system in its first two years than the decade-long home-grow regime that preceded it.

"Canadians authorized to medicate with cannabis should have the ability to grow their own supply if they want to take that on," said Mark Zekulin, Tweed's president. "It's our job as a licensed producer to provide a consistent and convenient choice for the majority of people who will choose to purchase from a regulated source rather than setting up a grow-op in their house. Our focus will remain on a products and services to set us apart."

In order to maintain its award-winning customer service levels in a growing market, Tweed is also pleased to announce it has completed the expansion of its customer care centre at the company's Smiths Falls location.

"There are many companies to choose from so we've long known that the way to stay ahead of the curve is through product variety and meaningful customer experiences. This expansion to house our team of over 35 trained customer care representatives will allow us to improve that experience for new and existing customers," continued Mr. Zekulin.

Here's to future growth, at home or at Tweed.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

Emil

20.04.2016 19:27
Bild des Benutzers 2brix
Offline
Kommentare: 1647

2.88 +0.33 (12.94%)  On 4/20, Tweed Apologizes to Cannabis Advocates in CanadaApril 20, 2016 at 10:13 am 

Canada is likely to be the first major countries to legalize cannabis for adult-use, but the nation is struggling with how to create a system that works for all.  The country’s federally legal cannabis program, MMPR, has seen several court challenges that have led Health Canada to address changes, including the provision for extracts (previously prohibited) and the pending inclusion of home-grown cannabis.  Still, there is tremendous divisiveness.  Canopy Growth’s Mark Zekulin, President of Tweed, posted an editorial today that is quite remarkable, as it accepts some of the blame for the divisiveness:

As we mark 4/20, the nationwide counterculture day to celebrate the benefits of the whole plant marijuana, advocates on both the medical and recreational fronts still flounder in debate weighing risk versus opportunity of the bud.

Tweed, as the largest legal producer of cannabis in the country, has played its role in this division. We firmly believe that all cannabis production and sale for commercial purposes should be strictly controlled and highly regulated. But this has manifested itself into a far too adversarial relationship with the founding cannabis community, something we must reset if we are to ensure a smart, progressive and open dialogue on cannabis policy.

This division has overshadowed the respect we have for the early advocates for progressive cannabis policy and for this, we apologize.

He discusses how Tweed is already working with many different parties and ends on a promising note:

There may well be a role for all of us – pharmacists, early cannabis activists and companies like Tweed that have invested tens of millions of dollars in cannabis research, clinical trials and production and distribution facilities.

Read Mark Zekulin’s “Let’s clean up the patchwork of rules governing marijuana”: http://www.theglobeandmail.com/report-on-business/rob-commentary/lets-clean-up-the-patchwork-of-rules-governing-marijuana/article29677006/

 

15.04.2016 18:24
Bild des Benutzers Emil
Offline
Kommentare: 604

Als die noch TWEED hiessen war ich noch nicht dabei, aber der Name war super.

Gesehen: WinkSmile

http://www.newswire.ca/news-releases/canopy-growth-corporation-announces-closing-of-bought-deal-financing-575836941.html

Emil

07.04.2016 21:47
Bild des Benutzers Selector
Offline
Kommentare: 286

Hier noch etwas News:

 

Eigentlich müsste der Kurs auch mal hochgehen, sonst kriege ich den Verleider.

 

Canopy Growth hires XIB for corporate development

 

2016-04-07 07:18 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION ENTERS AGREEMENT WITH XIB CONSULTING INC.

Canopy Growth Corp. has entered into an engagement agreement with XIB Consulting Inc. to assist Canopy Growth with corporate development initiatives, including, but not limited to, acquisitions, strategic networking and market awareness.

"We made a number of strategic acquisitions over the past two years to leverage large-scale production platforms, brand diversity and innovative customer engagement. These acquisitions have helped Canopy become a dominant marijuana company in Canada," said Bruce Linton, chairman and chief executive officer, Canopy Growth.

Added Mr. Linton: "The principals at XIB have developed a broad network and in-depth knowledge and experience in the sector. They will assist us in evaluating the landscape as we explore additional opportunities to expand our leadership position.

"We look forward to working with Canopy Growth as it continues to build upon its unique and scalable portfolio of cannabis brands and world-class cannabis production platforms," said Sean McNulty, principal at XIB.

Subject to the approval of the TSX Venture Exchange and pursuant to the engagement agreement, which has an initial term of six months, the company shall satisfy the engagement fee payable to XIB by issuing 38,656 common shares in the capital of Canopy Growth to XIB, which may be credited against incremental success fees payable under certain circumstances. The common shares will be issued at a price of $2.59 per share.

The appointment of XIB as a consultant of Canopy Growth and the corresponding share issuance remains subject to standard regulatory acceptance of applicable filings with the TSX Venture Exchange.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

31.03.2016 15:41
Bild des Benutzers Selector
Offline
Kommentare: 286

Was uns heut doch ausserordentlich freut: Biggrin

 

Canopy Growth receives licence to produce dried pot

 

2016-03-31 07:18 ET - News Release

 

Mr. Bruce Linton reports

TWEED FARMS ACHIEVES MAJOR MILESTONE - 375 000 SQ. FT. NOW APPROVED FOR DRIED MARIJUANA PRODUCTION AND PROCESSING

Tweed Farms Inc., a wholly owned subsidiary of Canopy Growth Corp., is now licensed to produce, possess and ship dried marijuana at its facilities in Niagara-on-the-Lake, Ont.

The license completes a successful phase of infrastructure enhancements that have increased the independence of the Tweed Farms site and transformed it from a broad-scale production facility to a vertically integrated campus capable of growing, trimming, curing and storing product. A 25,000 sq. ft. processing and storage building has been added to the existing 350,000 sq. ft. greenhouse. Tweed Farms will seek a final sales license as soon as its first crop has been harvested and tested for sale.

"We acquired the greenhouse twenty two months ago to position ourselves as a large scale, low-cost producer capable of supplying a sizeable percentage of the market," said Bruce Linton, CEO of Canopy Growth. "This infrastructure completion and Health Canada approval milestone is a testament to the team at Tweed Farms who continue to execute our capacity-building as planned."

"We now have three distinct facilities licensed to produce a significant amount of finished goods, offering a growing number of patients a reliable, diverse and secure supply of cannabis and related oils products," continued Linton.

Using tissue culture propagation rather than clones clipped from mother plants, large plots of cost-effective greenhouse space can be brought online to satisfy demand.

The license is valid through January 13 th, 2017 and allows Tweed Farms to produce 1200kg of dried marijuana. Consistent with Health Canada's process, Tweed Farms will seek to expand the licensed capacity based upon actual production from the initial 1,200kg.

Here's to (a whole lot more) Future Growth.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

24.03.2016 18:28
Bild des Benutzers Emil
Offline
Kommentare: 604

http://www.cannabisinvestingevent.com/?scode=035323

Bin auch am Mitlesen und siehe da, du bist nicht allein SmileWink

Seit heute bin ich sogar Besitzer einer Gesundheits-Kifferinvestition Blum 3

Yes 3

Friedliche Dinge gefallen mir besser und man entlässt hier auch keine Leute........

Emil

23.03.2016 09:18
Bild des Benutzers logn
Offline
Kommentare: 292

Selector hat am 23.03.2016 - 09:14 folgendes geschrieben:

Wo sind denn die vielen Aktionäre von hier geblieben, seid ihr noch dabei?

News:

 

Canopy Growth arranges $10-million bought deal

 

2016-03-22 16:13 ET - News Release

 

Mr. Tyler Burns reports

CANOPY GROWTH CORPORATION ANNOUNCES $10 MILLION BOUGHT DEAL

Canopy Growth Corp. has entered into a letter of engagement with Dundee Securities Ltd., on behalf of a syndicate of underwriters, under which the underwriters have agreed to purchase 4.35 million common shares of the company on a bought deal basis pursuant to the filing of a short form prospectus, subject to all required regulatory approvals, at a price per share of $2.30, for total gross proceeds of $10,005,000.

The company has agreed to grant the underwriters an overallotment option to purchase up to an additional 652,500 shares of the offering at the offering price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the offering. If this option is exercised in full, an additional $1,500,750 will be raised pursuant to the offering, and the aggregate proceeds of the offering will be $11,505,750.

The company intends to use the net proceeds of the offering for capital expenditures and for working capital and general corporate purposes.

The shares will be offered by way of a short form prospectus to be filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101, short form prospectus distributions.

The closing date of the offering is scheduled to be on or about April 15, 2016, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

Klar - ich habe zwischenzeitlich noch einen Order platziert.

Bin aber nur noch stiller Leser, da ich mit Cash.ch so meine Probleme habe. Falls ich die Position auflöse bzw. einen Verkauf in Erwägung ziehe, werde ich dies hier mitteilen. Möchte mich aber herzlich bei Dir bedanken! Ich verfolge deine Kommentare - also hör bitte nicht auf damit Wink

Wünsche einen angenehmen Tag.

23.03.2016 09:14
Bild des Benutzers Selector
Offline
Kommentare: 286

Wo sind denn die vielen Aktionäre von hier geblieben, seid ihr noch dabei?

News:

 

Canopy Growth arranges $10-million bought deal

 

2016-03-22 16:13 ET - News Release

 

Mr. Tyler Burns reports

CANOPY GROWTH CORPORATION ANNOUNCES $10 MILLION BOUGHT DEAL

Canopy Growth Corp. has entered into a letter of engagement with Dundee Securities Ltd., on behalf of a syndicate of underwriters, under which the underwriters have agreed to purchase 4.35 million common shares of the company on a bought deal basis pursuant to the filing of a short form prospectus, subject to all required regulatory approvals, at a price per share of $2.30, for total gross proceeds of $10,005,000.

The company has agreed to grant the underwriters an overallotment option to purchase up to an additional 652,500 shares of the offering at the offering price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the offering. If this option is exercised in full, an additional $1,500,750 will be raised pursuant to the offering, and the aggregate proceeds of the offering will be $11,505,750.

The company intends to use the net proceeds of the offering for capital expenditures and for working capital and general corporate purposes.

The shares will be offered by way of a short form prospectus to be filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101, short form prospectus distributions.

The closing date of the offering is scheduled to be on or about April 15, 2016, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

15.03.2016 16:42
Bild des Benutzers Selector
Offline
Kommentare: 286

Da kommen auch noch heute Firmen-News, die interessant sind:

 

 

Nutritional finishes 2nd phase of consulting for Canopy

 

2016-03-15 09:30 ET - News Release

See News Release (C-EAT) Nutritional High International Inc

Mr. David Posner of Nutritional High International reports

NUTRITIONAL HIGH AND CANOPY GROWTH CORP. JOINT PRESS RELEASE: SECOND PHASE OF CONSULTING UNDERTAKEN BY NUTRITIONAL HIGH FOR CANOPY GROWTH

Nutritional High International Inc. has successfully completed the second phase in its consulting for Canopy Growth Corp., a company formed when Tweed Marijuana Inc. acquired Bedrocan Cannabis Inc.

Nutritional High assisted Canopy Growth in evaluating different extraction processes and their variant components with a focus on maximizing oil extract yield from the cannabis plant. The involvement of Nutritional High with Canopy Growth demonstrates the recognition of Nutritional High's oil extraction expertise, and Nutritional High would welcome the opportunity to work with Canopy Growth in the future to share its extraction proficiency, which is a core of Nutritional High's business.

Bruce Linton, chief executive officer of Canopy Growth, commented:"We appreciate the assistance of Nutritional High as we advance our extraction operations. Their personnel provided us with valuable insight."

David Posner, CEO of Nutritional High, commented: "It is great to have the opportunity to demonstrate our skill set to a market leader such as Canopy. We are sure that they will be successful in the Canadian marketplace, and we are proud to be assisting. As Canada's licensing regime and oils and edibles rules and regulations develop further, we look forward to deepening our involvement in the Canadian marketplace."

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

15.03.2016 09:15
Bild des Benutzers Selector
Offline
Kommentare: 286

http://www.newswire.ca/news-releases/canopy-growth-corporation-issues-options-572059501.html

Wird wohl dem Kurs auf die Sprünge helfen?.........

 

SMITHS FALLS, ON, March 14th, 2016 /CNW Telbec/ - Canopy Growth Corporation (TSXV: CGC) ("Canopy Growth" or "the Corporation") has granted an aggregate of 550,00 options to purchase common stock to three Officers of the Corporation to be vested in accordance to the terms of the Corporation's Option Plan. In addition, 400,000 options were granted to purchase common stock to four Directors of the Corporation to be vested quarterly over one year.  All of the foregoing options shall have an exercise price equal to $2.95 per share.

On February 11, 2016, Tweed Inc. (Tweed), a wholly-owned subsidiary of Canopy Growth announced that it had entered into a business partnership with the artist known as Snoop Dogg. Under the partnership, Snoop Dogg, through a controlled company, and Tweed have partnered on curated content and brand strategy exclusively in Canada. The license agreement is for a term of up to five years. As partial consideration for the arrangement, the controlled company will receive a combination of Canopy Growth shares, royalties, and monetary compensation, released over the course of the agreement. The share consideration is comprised of common shares totaling 386,100 at a price of $2.59 per share, of which 135,135 common shares were issued on February 11, 2016 with the remainder of the 250,965 common shares escrowed for release, subject to meeting certain service criteria, over the initial three years of the term.

About Canopy Growth Corporation
Canopy Growth is Canada's first publicly traded medical marijuana company and the first geographically diversified producer with dual licenses under the Marihuana for Medical Purposes Regulations. Through its wholly-owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, the Company operates three state-of-the-art production facilities in Ontario and distributes marijuana across the country to Canadian patients managing a host of medical conditions. The Company is dedicated to educating healthcare practitioners, providing consistent access to high quality medication, conducting robust clinical research, and furthering the public's understanding of how marijuana is used for medical purposes. www.canopygrowth.com

About Tweed Inc.
Tweed Inc. is a Canadian company licensed under the Marihuana for Medical Purposes Regulations to produce and sell marijuana to authorized medical customers. Tweed strives to supply a wide selection of marijuana, as diverse as the patients who trust the company with their patronage. www.tweed.com

SOURCE Canopy Growth Corporation
 

For further information: Tyler Burns, Tyler.burns@canopygrowth.com, 1-855-558-9333 ex 122; Director: Bruce Linton, tmx@tweed.com

RELATED LINKS
http://canopygrowth.com/

09.03.2016 16:53
Bild des Benutzers Selector
Offline
Kommentare: 286

News: Wink step by step........

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2352833

INNOVATIVE INSURAINCE CONCIERGE SERVICE LAUNCHED BY BEDROCAN CANADA AND CFAMM

Canopy Growth Corp. unit Bedrocan Canada Inc. is launching a personalized insurance claim concierge service in collaboration with Canadians for Fair Access to Medical Marijuana.

Jonathan Zaid, the executive director of CFAMM and the first Canadian to have his medical cannabis covered by a group insurance plan, will work with a group of Bedrocan clients to identify individuals who may be able to attain coverage under their pre-existing insurance plans.

Cannabis costs have been routinely covered in some instances, most notably under the Veterans Affairs health plan. Canadians who have injured themselves on the job have also been granted coverage under provincial workers compensation boards on a case-by-case basis. These are positive signs that can and should be built upon.

"Medical cannabis should be covered like every other medication, yet patients often struggle to obtain coverage under their health plans," said Mr. Zaid. "This partnership with Bedrocan Canada we hope will help enable patients to successfully advocate for coverage."

Cannabis has been clinically proven to effectively treat a number of symptoms associated with serious conditions such as human immunodeficiency virus and acquired immune deficiency syndrome, cancer, multiple sclerosis, and chronic pain, yet its users continue to be denied coverage by the insurance industry.

"We see this is as an important first step in a larger process. Our hope is this personalized service will help to identify case studies that will successfully engage insurance companies in understanding both the therapeutic and economic benefits of medical cannabis use. The goal is to lay the groundwork in the short term while leading to cost coverage for tens of thousands of Canadians in the long run," said Marc Wayne, Bedrocan Canada president. "Whether you're a Bedrocan customer or not, we are working with medical cannabis patients across Canada to address this inconsistency."

In order to apply for the concierge service, Bedrocan Canada clients are asked to fill out a short survey. The data will be used to identify applicants who may be eligible for some form of insurance coverage. Although participants will be identified based on their potential eligibility for insurance coverage, the organizations will leverage individual cases that can lead to systemic change across the industry.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

03.03.2016 11:43
Bild des Benutzers Selector
Offline
Kommentare: 286

Was man noch wissen sollte von TWEED, könnte wichtig sein für solche, die sich wirklich damit auseinandersetzen: Wink

 

Tweed Inc., a subsidiary of Canopy Growth Corp., wishes to issue a clarifying release. A recent press release issued by a company called Quantum 9 indicates that Tweed endorses its services. In fact, no member of the Tweed's management team knows who Quantum 9 is.

In late 2013 a Tweed employee held a brief meeting with Quantum 9. Some years later, that individual penned a personal recommendation letter.

Tweed is proud of its accomplishments and the reputation it has built as a leader in the cannabis sector, and it has had the privilege of teaming up with real world-class leaders as it builds something special.

Tweed has partnered with DNA Genetics, an award-winning powerhouse of genetics and breeding in the cannabis sphere. It has teamed up with the Canadian AIDS Society to bring education initiatives to patients seeking answers, and with DSG Inc. to build the backbone of the Equal clinical study. It has worked closely with Indoor Harvest to explore groundbreaking aeroponics technology. It has incredible research partners at leading Canadian universities, and most recently it partnered with cannabis icon Snoop Dogg.

Quantum 9 does not fit into that category, and the company does not endorse or recommend its services.

© 2016 Canjex Publishing Ltd. All rights reserved. 

02.03.2016 13:56
Bild des Benutzers Selector
Offline
Kommentare: 286

Doch ja, ist angekommen, man hat richtig geschaut.

News:

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2351128

 

Canopy Growth's Bedrocan to sell vaporizers at cost

 

2016-03-02 07:28 ET - News Release

 

Mr. Bruce Linton reports

BEDROCAN CONTINUES COMMITMENT TO AFFORDABILITY

Bedrocan Canada, a wholly owned subsidiary of Canopy Growth Corp., is continuing its commitment to affordable medical cannabis treatment by offering vaporizers at cost. The offer, available to all registered Bedrocan Canada clients, is a part of a wider effort to reduce the cost of medicating with cannabis.

"Bedrocan is fully engaged with the medical community and respects the concern many physicians have with inhaling burnt plant matter as a means to medicate," said Marc Wayne, Bedrocan Canada's President. "Offering deep discounts on vaporizers is a way to address this concern by making alternative therapy applications more affordable."

Bedrocan Canada already offers the most affordable full line of standardized cannabis varieties in the country. Via true compassionate pricing, all Bedrocan varieties cost $5 per gram for all registered clients.

"Bedrocan Canada is and will always be a medical cannabis company," said Bruce Linton, chief executive officer of Canopy Growth. "Canada's cannabis laws are evolving but Bedrocan Canada is focused on advancements on the medical side of the industry. By advocating for tax amendments, co-ordinating research initiatives and facilitating physician education, the team at Bedrocan Canada remains focused on its core business."

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

Mobile

 

25.02.2016 20:27
Bild des Benutzers 2brix
Offline
Kommentare: 1647

Selector hat am 25.02.2016 - 14:59 folgendes geschrieben:

Wie das insgesamt aufgenomen wird?

 

http://www.newswire.ca/news-releases/canopy-growth-corporation-reports-t...

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2348793

versteh die aufstellung wiedermal nicht. increased wär ja super, aber scheint nicht sonderlich gut anzukommen. Riesen Enttäuschung ist aber auch nicht.

25.02.2016 14:59
Bild des Benutzers Selector
Offline
Kommentare: 286
Q3 per 31.12.2015
24.02.2016 21:10
Bild des Benutzers Selector
Offline
Kommentare: 286

Bitteschön, macht keine Mühe.

 

 

Good Kurz noch diese nette News (morgen dann Earnings CGC):

 

Canopy Growth unit receives cannabis oil licence

 

2016-02-24 09:07 ET - News Release

 

Mr. Mark Zekulin reports

TWEED LAUNCHES 10:1 CANNABIS OILS - LAUNCH COINCIDES WITH FIRST-OF-ITS KIND COMMITMENT TO RESPONSIBLE USE EDUCATION FUNDING BY CANOPY GROWTH COMPANIES

Tweed Inc., wholly owned subsidiary of Canopy Growth Corp., has received its licence to sell cannabis oil products. At noon tomorrow, the company will be launching the sale of high-quality 10:1 cannabis oils consisting of GMO-free organic sunflower oil and high-quality CO2-extracted cannabis oils.

Since its inception, Tweed has focused on producing an industry-leading variety of cannabis products that meet the needs of a diverse clientele. To date, that has meant growing a diverse selection of strains to ensure that patients find the strain that truly meets their personal needs. With 10:1 cannabis oils, the company will continue that focus and ensure that patients can still find the strain that is right for them, this time in a digestible format. Starting with popular offerings of Argyle, Princeton and Birds Eye, Tweed will introduce new strain-specific 10:1 cannabis oils on a continuing basis.

The name of the new product line, 10:1 cannabis oils reflects the ratio that each 10 millilitres of oil will contain the equivalent of one gram of the corresponding Tweed dried-flower variety. The company will sell 10:1 cannabis oils in 100 ml bottles.

"Introducing this new product category to our customers will undoubtedly come with a learning curve and ease of use and education was top of mind for us. Creating a simple, universal equivalency factor between flower and oil was the logical solution and a simple way to ensure customers can manage their dosing confidently," said Mark Zekulin, president, Tweed.

Tweed chose to balance 10:1 cannabis oils with organic, non-genetically modified sunflower oil because it is versatile enough to cook or bake with, hypoallergenic, and even good to ingest on its own as it comes.

Coinciding with the launch of 10:1 cannabis oils, Tweed and its sister company, Bedrocan Canada, are pleased to announce the launch of a fund to support the delivery of education programs on the responsible use of cannabis.

The companies will commit a combined $50,000 toward partnerships with leading organizations committed to responsible use education. In addition, Tweed and Bedrocan Canada will commit an additional $1, for every bottle of 10:1 cannabis oils sold, to this fund.

"Along with the launch of oils, we know that customers, health care practitioners, and education partners have a lot of questions, and we need to start building the resources to answer those questions using a systematic, Canada-wide approach," said Bruce Linton, chief executive officer of Canopy Growth. "As we move toward a non-medical consumer market, education on responsible use of cannabis will become all the more important, and as responsible companies we need to get out ahead of that curve."

Strain-specific 10:1 cannabis oils will be for sale at the Tweed website from $95 to $155 per bottle, or from $76 to $124 for patients qualifying for Tweed's compassionate pricing program.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

Quelle

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2348495

 

 

 

 

18.02.2016 19:19
Bild des Benutzers 2brix
Offline
Kommentare: 1647

wie immer besten Dank!

18.02.2016 17:18
Bild des Benutzers Selector
Offline
Kommentare: 286

News: (Wer das Unternehmen noch unter Tweed kannte, ist hier richtig).

 

Canopy Growth to provide Q3 results Feb. 25

 

2016-02-18 08:53 ET - News Release

 

Mr. Jordan Sinclair reports

CANOPY GROWTH TO ANNOUNCE THIRD QUARTER 2016 FINANCIAL RESULTS

Canopy Growth Corp. will release its financial results for the third quarter ended Dec. 31, 2015, on Feb. 25, 2016.

Following the release of its third quarter 2015 financial results, Canopy Growth will host a conference call with Bruce Linton, chief executive officer, and Tim Saunders, chief financial officer, at 8:30 a.m. Eastern Time the same day.

Calling information

 

Toll free dial-in number:  1-888-231-8191

International dial-in number:  647-427-7450

Conference ID:  55227314

 

Replay information

A replay of the call will be accessible by telephone until 11:59 p.m. ET on March 24, 2016.

 

Toll-free dial-in number:  1-855-859-2056

Replay password:  55227314

 

© 2016 Canjex Publishing Ltd. All rights reserved.

 

 

Weiter:

 

Canopy's Bedrocan renews licence for Toronto-area plant

 

2016-02-18 07:26 ET - News Release

 

Mr. Bruce Linton reports

BEDROCAN CANADA RECEIVES LICENSE RENEWAL; LAUNCHES NEXT PHASE OF AFFORDABILITY INITIATIVE

Bedrocan Canada Inc. has renewed the licence for its main production facility in the Toronto area. In addition, reasserting its commitment to affordable medicine, Bedrocan Canada is also announcing that its advocacy efforts to remove sales tax from medical cannabis have advanced to the House of Commons where a petition supporting the effort will be presented to Canada's lawmakers.

This is a promising step forward for a letter-writing campaign that started less than a month ago, respectfully asking Minister of Finance Bill Morneau to zero rate medical cannabis, thereby removing sales tax from its sale. Once achieved, this change will remedy an unjust financial burden on patients and bring a viable treatment option in line with the treatment of other prescription medicines.

Bedrocan Canada, a subsidiary of Canopy Growth Corp., is dedicated to advancing every aspect of medical cannabis, from clinical research to physician education. As Canada's cannabis laws evolve, Bedrocan Canada will remain committed to improving the body of knowledge, affordability and accessibility of medical cannabis.

"We are committed to advocating for patient issues and ensuring that the patient's voice does not get lost as a framework for non-medical cannabis is established," said Bruce Linton, chairman and chief executive officer of Canopy Growth. "Our commitment to affordability dates back to May, 2014, when we filed a request for review of this rule by the Canada Revenue Agency. This latest petition reflects our ongoing commitment to advance the issue of affordability however we can."

Bedrocan Canada's advocacy for fair tax treatment of medical cannabis follows closely on the introduction of true compassionate pricing, a flat $5 price for all varieties and all customers.

The company invites and encourages Canadians to visit the Parliament of Canada website to sign the petition and join as a partner in driving this important message forward.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

 

 

12.02.2016 14:20
Bild des Benutzers Selector
Offline
Kommentare: 286

Trotz Börsenturbulenzen hält sich dieser Kurs erstaunlich gut und das vermutlich schon mit Grund:

 

Canopy's Tweed enters licensing deal with Snoop Dogg

 

2016-02-12 06:27 ET - News Release

 

Mr. Jordan Sinclair reports

TWEED PARTNERS WITH ICONIC CANNABIS CONNOISSEUR SNOOP DOGG

Tweed Inc., a subsidiary of Canopy Growth Corp., has entered into a business partnership with entertainment icon Snoop Dogg.

Snoop Dogg is one of the world's most respected cannabis icons and pioneers in the industry. He is recognized as a connoisseur of quality, medical cannabis products, and has expanded his entrepreneurial endeavours to provide expertise and strategy to business ventures that, like Tweed, represent the birth of a new industry.

"There are real social and medical benefits from the cannabis industry -- and the world is seeing this positivity in a whole new way," said Snoop Dogg. "Canada has been at the forefront of the business model, and I look forward to being a part of the road ahead."

Under the partnership, Snoop Dogg, through a controlled company, and Tweed have partnered on curated content and brand strategy exclusively in Canada. The licence agreement is for an initial three-year term with a two-year extension. As partial consideration for the arrangement, the controlled company will receive a combination of Canopy shares, royalties and monetary compensation, released over the course of the agreement.

Snoop Dogg has truly paved the way across the global cannabis industry. In September, Snoop and business partner Ted Chung launched on-line media platform Merry Jane as the definitive cultural destination for cannabis news and original content. He was the first to release a widely lauded cannabis brand, Leafs By Snoop. And via Casa Verde Capital, Snoop Dogg is also recognized as a leading venture capitalist in the space -- investing in early-stage start-ups.

"Our team is proud to bring Snoop into the fold," said Mark Zekulin, Tweed's president. "Today we're announcing our partnership and welcoming him to one of Canada's most exciting industries. Over the coming months we'll unveil the specifics and until then all I can say is stay tuned."

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

26.01.2016 09:56
Bild des Benutzers Selector
Offline
Kommentare: 286

Latest News for all:

Gut zu wissen......

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2341918

 

Canopy Growth drops medical cannabis pricing

 

2016-01-25 14:07 ET - News Release

 

Mr. Cam Battley reports

BEDROCAN CANADA LAUNCHES TRUE COMPASSIONATE PRICING - REINFORCES ITS COMMITMENT TO AFFORDABLE MEDICINE

Bedrocan Canada Inc., a wholly owned subsidiary of Canopy Growth Corp., has made medical cannabis more affordable for all Canadian patients with a new price structure called true compassionate pricing. Under true compassionate pricing, all six cannabis varieties produced by Bedrocan Canada will be priced at $5 per gram, making it the most affordable product line in Canada.

Many Canadians who medicate with cannabis are doing so because traditional pharmaceutical drugs have not been as effective at treating their symptoms or have undesirable side effects. The decision to consume medical cannabis is made more complex due to the cost of the medicine.

"With limited insurance coverage and taxation, the affordability of medical cannabis can be a significant barrier to chronically ill patients obtaining the benefits of a medical marijuana program," said Jonathan Zaid, member of Bedrocan Canada's patient advisory board and executive director of Canadians for fair access to medical marijuana. "With its true compassionate pricing, Bedrocan is helping patients by making their medicine more affordable."

Bedrocan Canada currently produces six standardized whole-flower cannabis varieties that provide consistency and reliability to people managing a variety of medical conditions and symptoms. All strains are covered by the true compassion pricing promise and are guaranteed to be in stock.

"Bedrocan Canada's production methods have been refined over two decades to maximize yield and eliminate genetic variance from harvest to harvest. Because of that we're able to produce standardized varieties efficiently," said Marc Wayne, president of Bedrocan Canada. "Now that our Toronto facility is operating at full capacity, we are in a position to offer lower prices to our clients, the vast majority of whom are paying out of pocket for their medication."

Bedrocan Canada continues its active dialogue with the insurance industry to enhance insurance eligibility for medical cannabis and medical cannabis devices. The company is also encouraging the patient community to write to the federal government in an effort to change the current applicability of sales tax to medical cannabis, a policy that is inconsistent with the treatment of other health care practitioner authorized medications. Patients can visit Bedrocan's website to download a letter to Bill Morneau, Minister of Finance.

Working collaboratively, Bedrocan Canada strives to make medical cannabis more affordable for all Canadian patients.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

21.01.2016 16:05
Bild des Benutzers Selector
Offline
Kommentare: 286

 Wink Erfrischende News hier:

 

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2341236

Canopy's CannScience receives OK for pot research

 

2016-01-21 07:16 ET - News Release

 

Mr. Jordan Sinclair reports

CANNSCIENCE INNOVATIONS MOVES TO NEXT STAGE OF PRODUCT DEVELOPMENT

Canopy Growth Corp.'s CannScience Innovations Inc., operating through a strategic collaboration with the University Health Network, has obtained regulatory approval to conduct research on cannabis. Canopy Growth holds a 33-per-cent ownership stake in CSI through its October, 2015, acquisition of MedCannAccess.

As part of the launch of research and development activities, Tweed Inc., a wholly owned subsidiary of Canopy Growth, has made an initial transfer of cannabis to CSI.

"The current regulatory model has evolved to include non-inhaled forms of legal medical cannabis. Researching the next logical steps is a way to be ahead of the curve in a fast-paced industry," said Bruce Linton, chairman and chief executive officer of Canopy Growth.

With these approvals, and its collaboration with UHN, CSI intends to develop intellectual property related to extraction processes, methods to produce standardized products and new formulations. Once developed, CSI will initiate the required preclinical and clinical testing for approval of new therapeutic products by regulatory bodies in Canada and internationally. CSI may explore a number of product variants, including products related to its exclusive worldwide license of Generex Rapidmist technology platform to develop innovative cannabinoid delivery systems.

This is an important first step toward developing safer, standardized, metered products in non-smokable form that fit the definition of cannabis as medicine.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

Seiten